Artia Global Partners’s Ocular Therapeutix OCUL Stock Holding History

Artia Global Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-141,061	Closed	-$1.71M	–	56
2025 Q4	$1.71M	Hold	141,061	–	–	0.24%	41
2025 Q3	$1.65M	Buy	+141,061	New	+$1.69M	0.26%	36
2024 Q3	–	Sell	-500,000	Closed	-$3.42M	–	50
2024 Q2	$3.42M	Sell	500,000 -224,685	-31%	-$1.39M	0.66%	22
2024 Q1	$6.59M	Buy	724,685 +284,685	+65%	+$2.02M	1.33%	12
2023 Q4	$1.96M	Buy	+440,000	New	+$1.3M	0.57%	20

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artia Global Partners's OCUL Position: Q1 2026 in Review

Artia Global Partners sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 141,061 shares — an estimated $1.71M sold.

Artia Global Partners first reported a position in OCUL in Q4 2023 and held it in 5 quarters. The position peaked at $6.59M in Q1 2024. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Artia Global Partners reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Artia Global Partners sold 141,061 Ocular Therapeutix shares in Q1 2026, an estimated $1.71M.
Artia Global Partners first reported a position in Ocular Therapeutix in Q4 2023 and held it in 5 quarters.
Artia Global Partners's Ocular Therapeutix position peaked at $6.59M in Q1 2024.
271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.